{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-005460","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.886989+00:00","generated_at":"2026-05-27T14:02:24.185959+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Verastem exercises option for exclusive ex-Asia rights to KRAS G12D inhibitor VS-7375","bullets":["Exercised GenFleet option on Jan 14, 2025 for VS-7375, an oral, selective KRAS G12D (ON/OFF) inhibitor.","Rights cover worldwide development and commercialization outside mainland China, Hong Kong, Macau, and Taiwan.","Updated corporate presentation posted Jan 23, 2025; no specific financial or pipeline data disclosed in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-005460","json":"https://secwatch.observer/filing/0001104659-25-005460.json","markdown":"https://secwatch.observer/filing/0001104659-25-005460.md","text":"https://secwatch.observer/filing/0001104659-25-005460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925005460/0001104659-25-005460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925005460/tm254144d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T14:02:24.185959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}